2 Minute Read
Read the latest blog from our CCO Tim Murdoch, Why I Chose IntegriChain: A Journey from Tech Giants to Transforming Pharma Commercialization.
3 Minute Read
Read the latest on the CMS September Final Rule Overview & a Controversial 340B Rebate Policy
3 Minute Read
Katie Herrick and Dan Landis, consultants from Blue Fin Group, discuss how pharmaceutical companies are adapting to the changing healthcare environment by focusing on improving patient access and affordability.
4 Minute Read
Nick Lynch, Partner of Federal Compliance Solutions (FCS) discusses insights into recent developments in pharmaceutical pricing, focusing on government programs like 340B, Medicaid Drug Rebate Program (MDRP), Medicare Part...
6 Minute Read
Read the latest on Industry Updates, Biosimilar Barriers, and the Impact of Drug Price Negotiations.
4 Minute Read
Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
4 Minute Read
Read the latest on how states influence drug pricing and access, specialty pharmacies evolution to supoprt cell & gene therapies, and Walgreens entering the CGT arena.
3 Minute Read
Learn about the IRA's changes to Part D benefits have created uncertainty for both manufacturers and payers.
5 Minute Read
Discover the latest on IRA Part D Redesign Financial Implications, New Gene Therapies Give Newfound Hope for Patients, and Impact of Credit Card Fees in Government Pricing.